The program comprises six teams of MD Anderson researchers and clinicians initially focusing on these eight cancers:
- Acute myeloid leukemia/myelodysplastic syndromes
- Chronic lymphocytic leukemia
- Lung cancer
- Prostate cancer
- Triple-negative breast and high grade serous ovarian cancers
Each moon shot team is pursuing innovative projects prioritized for greatest patient impact, from basic and translational research to biomarker-driven clinical trials. Specialized platforms provide infrastructure, systems and strategy. The ultimate goal is to apply knowledge gained from this process to all cancers. Moon shot efforts will help support all other cancer research at MD Anderson, particularly with improved resources and infrastructure. Funding is from private philanthropy, institutional earnings, competitive research grants and commercialization of new discoveries.
As of July 31, private philanthropic commitments to the program total more than $287.8 million.